

19 July 2021

## 2021/22 Invitation to Tender

Te Pātaka Whaioranga, Pharmac, has released the draft 2021/22 Invitation to Tender for consultation and is welcoming feedback from patient groups and the public by 4 pm (New Zealand time), Monday 16 August 2021. For the medicines we are considering tendering, Pharmac wants feedback from patient groups and the public about:

- A proposal to tender certain medicines for principal supply;
- The implications of awarding Principal Supply Status (PSS); and
- The draft process and terms and conditions for the 2021/22 Invitation to Tender (2021/22 Tender).

Demand for medicines we fund, and for new and innovative medicines, is always increasing. Pharmac's Annual Tender is key in making sure we're able to keep up with that demand. Pharmac releases the draft Invitation to Tender each year at this time to consult on products which may be included in the Annual Tender. The Annual Tender is invaluable in ensuring we secure medicines (and some medical devices) for New Zealanders, manage spending on medicines and make sure the medicines we fund through the Tender are suitable for people to use.

The consultation on the draft 2021/22 Invitation to Tender is the first step in this process and is a chance for our stakeholders to provide feedback on the proposed products that could be included in the Annual Tender process. Pharmac welcomes all feedback on the draft 2021/22 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC and would be considered by the Pharmac Board (or its Delegate, where applicable) prior to making a decision on this proposal.

You can view the draft 2021/22 Invitation to Tender and full product list on the [Pharmac website](#), and provide feedback via email to [tender@pharmac.govt.nz](mailto:tender@pharmac.govt.nz).

### Background

Since 1997 Pharmac has been using the strategy of tendering medicines for sole supply of medicines for a fixed period of time. Regular tendering has proven to be an effective way to encourage competition among suppliers of medicines. As in the past, the community and hospital tender processes would be run in unison, however, the medicine list for community and hospital supply may be different.

We are seeking feedback on the approach outlined in the following pages, in particular on:

- The proposed tender process and timeline;
- The actual or potential clinical implications of awarding PSS to the medicines listed in Schedule Two, particularly the impact of a brand change on patients, their families and whānau;
- Your views on which medicines included in Schedule Two (or associated medical conditions) might have a particular need for funding of an alternative brand, and what the criteria for funding an alternative brand should be; and
- Your views on whether any product included in Schedule Two might have more than 5% of patients needing to access an alternative brand.

**ALL RESPONSES ARE DUE BY 4 PM (NEW ZEALAND TIME), MONDAY 16 AUGUST 2021**

Feedback should be provided to the Tender Analysts via email at [tender@pharmac.govt.nz](mailto:tender@pharmac.govt.nz)

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. Pharmac will give due consideration to any such request.

### **Distribution of Consultation Documents**

Although this consultation letter has been widely distributed, should you consider that a particular person, group or agency should receive this letter and/or future tender documents, please feel free to contact Pharmac or refer it on directly. All tender documents and consultations are also available from the Pharmac website at <https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/>). We also invite any person or group to contact Pharmac should you wish to meet to discuss the proposals contained in this consultation letter.

### ***Details of the proposed 2021/22 Tender***

In accordance with Pharmac's objective (to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided), Pharmac is consulting on a proposal to tender certain medicines for supply to community pharmacies and/or DHB hospital pharmacies. If Pharmac awards a tender for these products, the awarded brand would be the principal funded brand in the community and hospitals.

The full product list (Schedule Two) is a list of medicines that we are considering tendering. Medicines are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each medicine has a 'C' and/or 'H' next to it to indicate whether it is proposed to be tendered for community and/or hospital supply.

In general, the proposed 2021/22 Tender process would be similar to the 2020/21 Tender in that the 2021/22 Tender would result in awarding Principal Supply Status instead of Sole Supply Status or Hospital Supply Status.

A copy of the draft 2021/22 Invitation to Tender is available on our website: <https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/>, or by contacting Pharmac.

### **Key Aspects of Principal Supply Status:**

- PSS can apply across community and/or hospital markets (as detailed in Schedule Two).
- The tender winning brand will be the only brand subsidised in the community and/or purchased by DHB hospitals (subject to any alternative brand allowance) for up to approximately 3 years. The PSS period would conclude on 30 June 2025 for all Tenders awarded from the 2021/22 Tender.
- Other brands can continue to be marketed, sold and dispensed during the PSS period, but they would not necessarily receive a subsidy in the community.
- Any pharmaceutical that currently carries an additional patient charge (above that of the patient co-payment) in Section B would become fully subsidised if a tender is awarded for that pharmaceutical.

### **Alternative brands**

- The shift to PSS that we implemented in the previous Tender enables Pharmac greater flexibility to fund alternative brands for those who may experience, or are at heightened risk of, adverse clinical outcomes as a result of a brand change.

- DHB hospitals continue to be able to purchase alternative brands up to a certain percent of volume, similar to the Discretionary Variance provisions of Hospital Supply Status.
- PSS allows Pharmac the flexibility to fund alternative brands in the community:
  - In some cases, this would be through listing (or maintaining the listing of) other brands under Special Authority criteria.
  - In others, we would manage case-by-case approvals through our exceptional circumstances framework.
  - Regardless of the mechanism used, we intend to develop and communicate clear clinical criteria for funding of alternative brands.
- Brand changes are generally well-tolerated, and we expect that the need for funding of alternative brands will vary by product and will not always be predictable. With that in mind, we are interested in receiving feedback on:
  - Which chemicals (or indications for a chemical) or patient groups might have particular need for funding of an alternative brand (and why), and
  - For those situations, whether you consider that clinical destabilisation can be objectively determined, and if so, how.
- The draft contractual terms for the 2021/22 Tender do not put a cap on the number of patients for whom Pharmac might fund an alternative brand, however the draft contractual terms include a threshold (indicated by the “ABA Limit” in Schedule Two) above which suppliers would be reimbursed for lost market share. Accordingly, we are interested to understand if you consider that there are any products that we are proposing to tender where more than 5% of patients might need access to an alternative brand.
- Note that although PSS would give Pharmac the option to fund alternative brands, continued supply of a particular alternative brand cannot always be guaranteed.



## Key Dates and Timeframes for the 2021/22 Tender:

The proposed timelines for the 2021/22 Tender are as follows:

Date	Event
19 July 2021	Consultation with suppliers, medical groups, patients and interested parties on the proposed medicine list and draft 2021/22 Tender.
11 August 2021	Final date for receipt of Alternative Commercial Proposals (ACPs) to tendering by Pharmac.
16 August 2021	Final date for all consultation to be received.
August/September 2021	Pharmac considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet Pharmac's Factors for Consideration, and enters into provisional contracts with suppliers where appropriate.
September 2021	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
September/October 2021	Consultation and decisions on Alternative Commercial Proposals.
Early November 2021	Issuing of the 2021/22 Tender.
16 December 2021	Invitation to Tender closes.
From end of January 2022	Announcements on 2021/22 Tender decisions will commence.

## Contractual obligations for suppliers

A copy of the draft terms and conditions which would form the terms of the 2021/22 Tender contract is available on the Pharmac website: <https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/>

## Additional Special Terms

### *Intra-uterine copper devices*

Additional Special Terms have been included in the draft 2021/22 Tender contract for intra-uterine copper devices (Schedule Seven). This clause requires any potential suppliers to offer education, training and support resources to patients and healthcare professionals. This clause also outlines the additional information suppliers must provide relating to their Tender Bid. The full Additional Special Terms for intra-uterine copper devices can be found in the draft 2021/22 Tender contract on the Pharmac website.

### *Long-acting filgrastim*

Long-acting filgrastim has been included in the draft 2021/22 Tender. Pharmac would consider bids for any long-acting filgrastim product (e.g. pegfilgrastim, pegfilgrastim

biosimilars, and lipegfilgrastim) for this market; all of which would be subject to the same access criteria<sup>1</sup>. Pharmac would reserve the right to award the tender to one long-acting filgrastim product for the entire market.

## Schedule Two: Possible medicines for tender for principal supply

### Order of medicines in this Schedule

Medicines have been listed in groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of these groups, and the corresponding page numbers for your ease of reference. Medicines with indications that may apply to multiple therapeutic groups will only appear in one group.

<i>Therapeutic Group</i>	<i>Page Numbers</i>
Alimentary Tract and Metabolism	9
Blood and Blood Forming Organs	9-10
Cardiovascular System	10-11
Dermatologicals	11-12
Extemporaneously Compounded Preparations	12-13
Genito-Urinary System	13
Hormone Preparations – Systemic Excluding Contraceptives	13-14
Infections – Agents for Systemic Use	14
Musculoskeletal System	14-15
Nervous System	15-17
Oncology and Immunosuppressants	18
Respiratory System and Allergies	18
Sensory Organs	18-19

### Information provided for each medicine

For each medicine (as defined by chemical name, form and strength) we have provided the following information:

- the current ex-manufacturer subsidy per unit of measure as at 1 July 2021;
- the number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2021;
- an estimate of the annual community market value at current subsidies (estimated by multiplying the volume of units subsidised in the year ending 30 June 2021 by the relevant listed unit subsidy as at 1 July 2021); and

<sup>1</sup> A decision on whether to revert to the 20% threshold was deferred in [August 2020](#). A decision on whether to maintain or amend the access criteria is expected to be made over the coming months subject to clinical advice

- comments specifically relating to the Tender Item and/or its current listing on the Pharmaceutical Schedule.

### Hauora Arotahi - Māori Health Areas of Focus

The draft 2021/22 Tender includes treatments for mental health, diabetes, heart health (high blood pressure and stroke), respiratory health, and cancer (lung and breast). These are the Māori health areas of focus as voiced by whānau Māori.

Te Pātaka Whaioranga (Pharmac) is continually working to develop and implement advances in these Hauora Arotahi, to best help achieve equitable health outcomes for Māori.

Cancer – Lung and Breast	
Chemical Name	Line Item(s)
Capecitabine	Tab 150 mcg Tab 500 mg
Fulvestrant	Inj 50 mg per ml, 5 ml
Thiotepa	Inj 15 mg Inj 100 mg

Heart Health – High Blood Pressure and Stroke	
Chemical Name	Line Item(s)
Chlorthalidone	Tab 25 mg
Clopidogrel	Tab 75 mg
Enalapril	Tab 5 mg Tab 10 mg Tab 20 mg
Losartan with hydrochlorothiazide	Tab 50 mg with hydrochlorothiazide 12.5 mg
Prasugrel	Tab 5 mg Tab 10 mg
Telmisartan	Tab/Cap 40 mg Tab/Cap 80 mg
Telmisartan with hydrochlorothiazide	Tab 40 mg with hydrochlorothiazide 12.5 mg  Tab 80 mg with hydrochlorothiazide 12.5 mg  Tab 80 mg with hydrochlorothiazide 25 mg
Tenecteplase	Inj 50 mg

Mental Health	
Chemical Name	Line Item(s)
Amisulpride	Tab 100 mg Tab 200 mg Tab 400 mg
Chlorpromazine hydrochloride	Inj 25 mg per ml, 2 ml ampoule Tab 10 mg Tab 25 mg Tab 100 mg
Clozapine	Oral liq 50 mg per ml
Fluoxetine hydrochloride [split market]	Cap 20 mg Tab dispersible 20 mg, scored
Haloperidol	Inj 5 mg per ml, 1 ml Oral liq 2 mg per ml Tab 500 mcg Tab 1.5 mg Tab 5 mg
Olanzapine	Inj 210 mg vial Inj 300 mg vial Inj 405 mg
Paroxetine	Tab 20 mg
Sertraline	Tab 50 mg Tab 100 mg
Tranylcypromine sulphate	Tab 10 mg

Respiratory Health	
Chemical Name	Line Item(s)
Cetirizine hydrochloride	Tab 10 mg
Loratadine	Tab 10 mg
Montelukast	Tab 4 mg Tab 5 mg Tab 10 mg



## Explanation of terms, symbols and abbreviations

Most terms and abbreviations used are self-explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

The following table explains the symbols used in the draft medicine list:

Symbol	Explanation
Underlined	Medicine line items where a sole supply or Principal Supply contract is in force are underlined. The price and subsidy for these medicines are fixed until 30 June 2022 unless otherwise stated in the Comments column and a listing of a new brand could only occur after that date.
C	To be tendered for Principal Supply Status (community medicines).
H	To be tendered for Principal Supply Status (DHB hospital medicines).
PCT	A reference in the Invitation to Tender that denotes the pharmaceuticals for which DHB hospitals may claim a subsidy through Section B of the Pharmaceutical Schedule.
+	Pharmac has been advised of the existence of a patent.
*	There is no fully funded product available for this line item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP) means a Medicine, marked with an “@”, for which the supplier of the successful Tender Bid would be required to hold additional stock.
#	A rebate currently exists.



## SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

### Alimentary Tract and Metabolism

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Ascorbic acid</b>					
<u>Tab 100 mg</u>	5,318,248	\$105,301	\$0.0198	C H 5%	
<b>Budesonide</b>					
Cap 3 mg Controlled Release	355,058	\$656,857	\$1.8500	C H 5%	Current restrictions would apply
<b>Calcitriol</b>					
<u>Cap 0.25 mcg</u>	1,315,967	\$104,619	\$0.0795	C H 5%	
<u>Cap 0.5 mcg</u>	573,877	\$78,908	\$0.1375	C H 5%	
<b>Citric acid with magnesium oxide and sodium picosulfate</b>					
Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet				H 5%	
<b>Ferrous Sulphate</b>					
Oral liq 30 mg (6 mg elemental) per ml	7,366,935	\$177,985	\$0.0242	C H 5%	There may be a preference for a child-resistant cap and a preference for a pack size of 500 ml or less.
<b>Glycopyrronium bromide</b>					
Inj 0.2 mg per ml, 1 ml	35,631	\$233,205	\$6.5450	C H 5%	
<b>Lactulose</b>					
<u>Oral liq 10 g per 15 ml</u>	194,957,294	\$1,298,416	\$0.0067	C H 5%	Preference for a pack size of 500 ml or similar.
<b>Loperamide hydrochloride</b>					
<u>Cap 2 mg</u>	10,090,445	\$157,663	\$0.0156	C H 5%	Pharmac reserves the right to award two separate tenders for capsules and tablets.
Tab 2 mg	2,339,878	\$62,884	\$0.0269	C H 5%	Pharmac reserves the right to award two separate tenders for capsules and tablets.
<b>Macrogol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate</b>					
Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet				H 5%	
<b>Multivitamins</b>					
<u>Tab (BPC cap strength)</u>	16,478,258	\$188,676	\$0.0115	C H 5%	
<b>Omeprazole</b>					
<u>Inj 40 mg ampoule with diluent</u>				H 5%	
<u>Inj 40 mg with diluent</u>	4,071	\$27,665	\$6.7960	C H 5%	
<b>Pantoprazole</b>					
<u>Tab EC 20 mg</u>	12,628,293	\$255,092	\$0.0202	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab EC 40 mg</u>	11,755,702	\$335,038	\$0.0285	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<b>Sodium citrate with sodium lauryl sulphoacetate</b>					
<u>Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml</u>	481,017	\$288,418	\$0.5996	C H 5%	Preference for a pack size of 50 enemas or less.
<b>Sulfasalazine</b>					
<u>Tab EC 500 mg</u>	6,219,595	\$965,903	\$0.1553	C H 5%	
<b>Zinc sulphate</b>					
<u>Cap 50 mg elemental</u>	1,394,155	\$153,357	\$0.1100	C H 5%	

### Blood and Blood Forming Organs

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Clopidogrel</b>					
<u>Tab 75 mg</u>	13,174,867	\$721,456	\$0.0548	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Blood and Blood Forming Organs**

<b>Chemical Name</b> Line Item	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
<b>Compound electrolytes</b>					
<u>Powder for soln for oral use</u>	1,346,619	\$263,129	\$0.1954	C H 5%	Units and unit subsidy expressed as 'per sachet'. There may be a preference for products to include a measuring device or to come in unit dose sachets. Preference for pack sizes of 10 - 20 sachet packs.
<b>Long-acting filgrastim</b>					
Inj 6 mg per 0.6 ml	12,083	\$13,049,640	\$1,080.0000	C H 5%	Special Authority restrictions may apply. Pharmac reserves the right to award a tender to one long-acting filgrastim product for the whole market, please refer to the consultation documentation. Units and cost shown are for pegfilgrastim.
<b>Prasugrel</b>					
Tab 10 mg	5,622	\$24,094	\$4.2857	C H 5%	Not currently listed in the Pharmaceutical Schedule. Special Authority restrictions may apply. Units shown are for a product delisted 1 February 2021.
Tab 5 mg	1,304	\$5,030	\$3.8571	C H 5%	Not currently listed in the Pharmaceutical Schedule. Special Authority restrictions may apply. Units shown are for a product delisted 1 February 2021.
<b>Sodium chloride</b>					
<u>Inj 0.9%. 5 ml</u>	106,913	\$14,968	\$0.1400	C H 5%	There may be a preference for plastic ampoules.
<u>Inj 0.9%. 10 ml</u>	600,519	\$64,856	\$0.1080	C H 5%	There may be a preference for plastic ampoules.
<u>Inj 0.9%. 20 ml</u>	165,274	\$41,319	\$0.2500	C H 5%	There may be a preference for plastic ampoules.
<b>Tenecteplase</b>					
Inj 50 mg				H 5%	
<b>Tranexamic acid</b>					
<u>Tab 500 mg</u>	3,325,185	\$523,717	\$0.1575	C H 5%	

**Cardiovascular System**

<b>Chemical Name</b> Line Item	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
<b>Adenosine</b>					
Inj 3 mg per ml, 2 ml vial				H 5%	
<b>Amiodarone hydrochloride</b>					
<u>Inj 50 mg per ml, 3 ml</u>	14,612	\$23,920	\$1.6370	C H 5%	
<u>Tab 100 mg</u>	507,706	\$64,311	\$0.1267	C H 5%	
<u>Tab 200 mg</u>	971,211	\$169,962	\$0.1750	C H 5%	
<b>Chlorthalidone [Chlorthalidone]</b>					
<u>Tab 25 mg</u>	4,814,887	\$625,935	\$0.1300	C H 5%	
<b>Digoxin</b>					
<u>Tab 250 mcg</u>	826,158	\$52,321	\$0.0633	C H 5%	
<u>Tab 62.5 mcg</u>	7,536,051	\$219,827	\$0.0292	C H 5%	
<b>Enalapril</b>					
<u>Tab 5 mg</u>	2,686,151	\$48,888	\$0.0182	C H 5%	Preference for a scored table, and for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 10 mg</u>	2,834,589	\$57,259	\$0.0202	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<u>Tab 20 mg</u>	3,537,107	\$85,598	\$0.0242	C H 5%	Preference for a pack size of 30 or 90 tablets in a bottle pack.
<b>Furosemide [Frusemide]</b>					
<u>Inj 10 mg per ml, 25 ml</u>	300	\$3,032	\$10.1083	C H 5%	
<u>Oral liq 10 mg per ml</u>	127,050	\$47,428	\$0.3733	C H 5%	

sole supply

#=rebate \* =part charge @ =ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Cardiovascular System**

<b>Chemical Name</b>			<b>Unit</b>			
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>	
<b>Furosemide [Frusemide]</b>						
<u>Inj 10 mg per ml, 2 ml</u>	10,264	\$2,361	\$0.2300	C H 5%		
<b>Iloprost</b>						
Inj 50 mcg per ml, 0.5 ml				H 5%		
<u>Nebuliser soln 10 mcg per ml, 2 ml</u>	23,100	\$569,877	\$24.6700	C H 5%	Special Authority restrictions may apply.	
<b>Losartan with hydrochlorothiazide</b>						
Tab 50 mg with hydrochlorothiazide 12.5 mg	7,732,270	\$484,581	\$0.0627	C H 5%		
<b>Metoprolol Tartrate</b>						
Inj 1 mg per ml 5 ml	1,786	\$9,466	\$5.3000	C H 5%		
<b>Nicorandil</b>						
<u>Tab 10 mg</u>	825,412	\$351,766	\$0.4262	C H 5%		
<u>Tab 20 mg</u>	115,476	\$62,126	\$0.5380	C H 5%		
<b>Nimodipine</b>						
Inj 0.2 mg per ml, 50 ml				H 5%		
Tab 30 mg				H 5%		
<b>Noradrenaline</b>						
Inj 1 mg per ml, 4 ml ampoule				H 5%		
<b>Sotalol</b>						
<u>Tab 80 mg</u>	3,711,424	\$241,836	\$0.0652	C H 5%		
<u>Tab 160 mg</u>	128,382	\$14,096	\$0.1098	C H 5%		
<b>Spironolactone</b>						
<u>Oral liq 5 mg per ml</u>	46,200	\$56,549	\$1.2240	C H 5%		
<b>Telmisartan</b>						
Tab/Cap 40 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.	
Tab/Cap 80 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.	
<b>Telmisartan with hydrochlorothiazide</b>						
Tab 40 mg with hydrochlorothiazide 12.5 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.	
Tab 80 mg with hydrochlorothiazide 12.5 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.	
Tab 80 mg with hydrochlorothiazide 25 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.	

**Dermatologicals**

<b>Chemical Name</b>			<b>Unit</b>			
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>	
<b>Adapalene</b>						
Crn 0.1%	293,850	\$224,208	\$0.7630#	C H 5%	Preference for a maximum pack size of 30 g.	
Gel 0.1%	497,460	\$379,562	\$0.7630#	C H 5%	Preference for a maximum pack size of 30 g	
<b>Benzoyl Peroxide</b>						
Gel/crm/soln/lotion 2.5% - 5%				C H 5%	Not currently listed in the Pharmaceutical Schedule.	
<b>Cetomacrogol with glycerol</b>						
<u>Crn 90% with glycerol 10%, 1,000 ml</u>	304,697,279	\$944,562	\$0.0031	C H 5%	Preference for sodium lauryl sulphate (SLS)-free presentation. There may be a preference for a pump bottle.	
<u>Crn 90% with glycerol 10%, 100 g</u>				H 5%	Preference for SLS-free presentation. There may be a preference for a pump bottle.	
<u>Crn 90% with glycerol 10%, 500 ml</u>	304,697,279	\$1,432,077	\$0.0047	C H 5%	Preference for SLS-free presentation. There may be a preference for a pump bottle.	

sole supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Dermatologicals**

<b>Chemical Name</b> Line Item	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
<b>Clobetasol propionate</b>					
<u>Crn 0.05% (pack size 30 g or less)</u>	3,739,290	\$271,734	\$0.0727	C H 5%	
<u>Oint 0.05% (pack size 30 g or less)</u>	3,599,730	\$254,393	\$0.0707	C H 5%	
<u>Scalp app 0.05%</u>	803,250	\$152,352	\$0.1897	C H 5%	
<b>Clotrimazole</b>					
Crn 1%	2,893,660	\$111,406	\$0.0385	C H 5%	
<b>Coal tar</b>					
<u>Soln BP</u>	145,429	\$26,359	\$0.1813	C H 5%	Preference for a pack size of 100 ml or less. Only in combination.
<b>Dimethicone</b>					
Crn 5% (pack size 100 g or less)				C H 5%	Not currently listed in Section B of the Pharmaceutical Schedule.
<u>Lotn 4% - head lice suffocant</u>	3,718,000	\$92,578	\$0.0249	C H 5%	
<u>Crn 5% (pack size greater than 100 g)</u>	3,935,200	\$35,259	\$0.0090	C 5%	There may be a preference for a pump bottle
Crn 10%	2,045,000	\$18,487	\$0.0090	C H 5%	There may be a preference for a pump bottle.
<b>Hydrocortisone</b>					
<u>Crn 1% (pack size greater than or equal to 15 g and less than or equal to 100 g)</u>				C H 5%	Preference for SLS-free presentation. Units and cost for the whole crn 1% market are shown below.
<u>Crn 1% (pack size greater than 100 g)</u>	22,032,198	\$822,462	\$0.0373	C H 5%	Preference for SLS-free presentation. Units shown are for the whole crn 1% market. Unit subsidy and cost shown are weighted based on pack size and usage. Units and cost for whole crn 1% market are shown below.
<b>Hydrocortisone with natamycin and neomycin</b>					
Crn 1% with natamycin 1% and neomycin sulphate 0.5%	2,142,600	\$478,507	\$0.2233	C H 5%	
<b>Paraffin</b>					
<u>White soft (pack size 2000 g or more)</u>	2,071,299	\$16,562	\$0.0080	C 5%	
<u>White soft (pack size 500 g or less)</u>	128,146	\$1,421	\$0.0111	C H 5%	
<b>Sunscreens, proprietary</b>					
<u>SPF 50+ or greater</u>	1,317,800	\$33,604	\$0.0255	C H 5%	Subsidy by endorsement only. Preference for a lotion, UVB SPF > 50, UVA SPF >30. Supporting evidence of protection level must be provided at Pharmac's
<b>Zinc and castor oil</b>					
Crn (pack size 50 g or less)				H 5%	
Oint (pack size 50 g or less)				H 5%	
Oint (pack size greater than or equal to 500 g)	19,187,874	\$163,097	\$0.0085	C H 5%	Units and subsidy shown are per the 500 g pack size currently listed.

**Extemporaneously Compounded Preparations**

<b>Chemical Name</b> Line Item	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
<b>Compound Hydroxybenzoate</b>					
Soln	43,561	\$13,068	\$0.3000	C H 5%	Units expressed as per 'ml'.
<b>Glycerin with sodium saccharin</b>					
<u>Suspension</u>	105,264	\$6,887	\$0.0654	C H 5%	
<b>Glycerin with sucrose</b>					
<u>Suspension</u>	343,137	\$22,451	\$0.0654	C H 5%	
<b>Methyl Hydroxybenzoate</b>					
<u>Powder</u>	1,639	\$589	\$0.3592	C H 5%	Preference for pack size 50 g or less.
<b>Methylcellulose</b>					
<u>Powder</u>	3,484	\$1,287	\$0.3695	C H 5%	

sole supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Extemporaneously Compounded Preparations**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Methylcellulose</b>					
<u>Suspension</u>	401,842	\$26,293	\$0.0654	C H 5%	
<b>Methylcellulose with glycerin and sodium saccharin</b>					
<u>Suspension</u>	1,442,989	\$94,415	\$0.0654	C H 5%	
<b>Methylcellulose with glycerin and sucrose</b>					
<u>Suspension</u>	1,876,817	\$122,800	\$0.0654	C H 5%	
<b>Sodium Bicarbonate</b>					
<u>Powder BP</u>	389,472	\$7,828	\$0.0201	C H 5%	Preference for pack size less than 100 g. Only for extemporaneously compounded omeprazole and lansoprazole suspension.
<b>Syrup (pharmaceutical grade)</b>					
<u>Liq</u>	87,358	\$2,612	\$0.0299	C H 5%	Only for extemporaneously compounded oral liquid preparations.

**Genito Urinary System**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Clotrimazole</b>					
<u>Vaginal crm 1% with applicators</u>	1,836,405	\$131,174	\$0.0714	C H 5%	
<u>Vaginal crm 2% with applicators</u>	1,615,335	\$242,300	\$0.1500	C H 5%	
<b>Ethinylloestradiol with Norethisterone</b>					
Tab 35 mcg with norethisterone 1 mg	2,569,894	\$212,628	\$0.0827	C H 5%	
<b>Intra-Uterine Copper Device</b>					
<u>IUD long</u>	4,101	\$63,566	\$15.5000	C H 5%	Pharmac reserves the right to award one, some or all presentations of intra-uterine copper device. Refer to Schedule 7 for additional Special Terms.
<u>IUD medium</u>	4,753	\$87,693	\$18.4500	C H 5%	Pharmac reserves the right to award one, some or all presentations of intra-uterine copper device. Refer to Schedule 7 for additional Special Terms.
<u>IUD short</u>	3,039	\$56,070	\$18.4500	C H 5%	Pharmac reserves the right to award one, some or all presentations of intra-uterine copper device. Refer to Schedule 7 for additional Special Terms.
<b>Levonorgestrel</b>					
0.75 mg - 1.5 mg	130,309	\$645,030	\$4.9500	C H 5%	
<b>Medroxyprogesterone acetate</b>					
<u>Inj long-acting 150 mg per ml, 1 ml syringe</u>	138,191	\$1,102,764	\$7.9800	C H 5%	
<b>Mifepristone</b>					
Tab 200 mg	2,011	\$60,330	\$30.0000	C H 5%	
<b>Mifepristone with misoprostol</b>					
Mifepristone 200 mg tablet x 1 and misoprostol 200 mcg tablet x4 [combination pack]				C H 5%	Not currently listed in the Pharmaceutical Schedule.
<b>Tamsulosin</b>					
<u>Tab 400 mcg</u>	4,314,131	\$764,895	\$0.1773	C H 5%	Special Authority restrictions may apply.
<b>Tolterodine tartrate</b>					
Tab 1 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.
Tab 2 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.

**Hormone Preparations - Systemic Excluding Contraceptive Hormones**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
----------------------------	-------	------	-----------------	-----------	----------

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Hormone Preparations - Systemic Excluding Contraceptive Hormones**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Dexamethasone phosphate</b>					
<u>Inj 4 mg per ml, 1 ml</u>	87,816	\$81,230	\$0.9250	C H 5%	
<u>Inj 4 mg per ml, 2 ml</u>	88,754	\$145,290	\$1.6370	C H 5%	
<b>Fludrocortisone Acetate</b>					
Tab 100 mcg	1,425,274	\$204,099	\$0.1432	C H 5%	
<b>Levothyroxine</b>					
Oral liq				C H 5%	Not currently listed in the Pharmaceutical Schedule. Special Authority restrictions may apply.
<b>Progesterone</b>					
Cap 100 mg	65,188	\$35,853	\$0.5500	C H 5%	

**Infections**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Amoxicillin</b>					
<u>Cap 250 mg</u>	618,576	\$27,836	\$0.0450	C H 5%	
<u>Cap 500 mg</u>	13,342,544	\$986,815	\$0.0740	C H 5%	
<b>Caspofungin</b>					
Inj 50 mg				H 5%	Pharmac reserves the right to award a tender to one strength of caspofungin injections for the whole caspofungin injection market.
Inj 70 mg				H 5%	Pharmac reserves the right to award a tender to one strength of caspofungin injections for the whole caspofungin injection market
<b>Cefaclor monohydrate</b>					
<u>Cap 250 mg</u>	1,716,311	\$423,929	\$0.2470	C H 5%	
<u>Grans for oral liq 125 mg per 5 ml</u>	2,322,319	\$81,978	\$0.0353	C H 5%	
<b>Cefalexin monohydrate</b>					
<u>Cap 250 mg</u>	340,920	\$56,763	\$0.1665	C H 5%	
Cap 500 mg	3,438,307	\$679,066	\$0.1975	C H 5%	
<b>Ceftriaxone sodium</b>					
<u>Inj 500 mg</u>	8,880	\$7,903	\$0.8900	C H 5%	
<u>Inj 1 g</u>	6,573	\$5,245	\$0.7980	C H 5%	
Inj 2 g				C H 5%	
<b>Clindamycin</b>					
<u>Cap hydrochloride 150 mg</u>	1,031,765	\$198,181	\$0.1921	C H 5%	
<u>Inj 150 mg per ml, 4 ml ampoule</u>	1,431	\$5,581	\$3.9000	C H 5%	
<b>Ertapenem</b>					
Inj 1 g vial				H 5%	
<b>Erythromycin Lactobionate</b>					
<u>Inj 1 g</u>	651	\$6,510	\$10.0000	C H 5%	
<b>Phenoxymethylpenicillin (Penicillin V)</b>					
<u>Grans for oral liq 125 mg per 5 ml</u>	196,651	\$5,880	\$0.0299	C H 5%	
<u>Grans for oral liq 250 mg per 5 ml</u>	1,724,832	\$68,821	\$0.0399	C H 5%	
<b>Voriconazole</b>					
Inj 200 mg vial				H 5%	

**Musculoskeletal System**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Alendronate sodium</b>					
<u>Tab 70 mg</u>	242,247	\$147,771	\$0.6100	C H 5%	

sole supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Musculoskeletal System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
Line Item					
<b>Alendronate sodium with cholecalciferol</b>					
<u>Tab 70 mg with cholecalciferol 5,600 iu</u>	774,556	\$292,395	\$0.3775	C H 5%	
<b>Pyridostigmine bromide</b>					
<u>Tab 60 mg</u>	583,414	\$267,145	\$0.4579	C H 5%	
<b>Risedronate sodium</b>					
<u>Tab 35 mg</u>	389,849	\$302,133	\$0.7750	C H 5%	
<b>Rocuronium bromide</b>					
Inj 10 mg per ml, 5 ml				H 5%	
<b>Tenoxicam</b>					
<u>Tab 20 mg</u>	468,216	\$42,842	\$0.0915	C H 5%	
<b>Zoledronic Acid</b>					
<u>Inj 5 mg</u>	1,558,400	\$935,040	\$0.6000	C H 5%	Special Authority restrictions may apply.

**Nervous System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
Line Item					
<b>Amisulpride</b>					
<u>Tab 100 mg</u>	327,938	\$56,297	\$0.1717	C H 5%	
<u>Tab 200 mg</u>	558,166	\$139,167	\$0.2493	C H 5%	
<u>Tab 400 mg</u>	48,302	\$23,974	\$0.4963	C H 5%	
<b>Aspirin</b>					
<u>Tab dispersible or soluble 300 mg</u>	779,380	\$35,072	\$0.0450	C H 5%	Pharmac may award an ABA limit of up to 25% in Section H of the Pharmaceutical Schedule.
<b>Bupivacaine hydrochloride with adrenaline</b>					
Inj 0.25% with 1:400,000 of adrenaline, 20 ml non-sterile pack				H 5%	
Inj 0.5% with 1:200,000 of adrenaline, 20 ml non-sterile pack				H 5%	
<b>Bupivacaine hydrochloride with fentanyl</b>					
Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag				H 5%	
Inj 1.25mg with 2 mcg fentanyl per ml, 100 ml bag				H 5%	
Inj 1.25mg with 2 mcg fentanyl per ml, 200 ml bag				H 5%	
<b>Buprenorphine with Naloxone</b>					
<u>Tab sublingual 2 mg with naloxone 0.5 mg</u>	545,953	\$358,184	\$0.6561	C H 5%	Special Authority restrictions may apply.
<u>Tab sublingual 8 mg with naloxone 2 mg</u>	522,915	\$992,043	\$1.8971	C H 5%	Special Authority restrictions may apply.
<b>Chlorpromazine Hydrochloride</b>					
<u>Inj 25 mg per ml, 2 ml ampoule</u>	3,183	\$9,800	\$3.0790	C H 5%	
<u>Tab 10 mg</u>	104,637	\$15,518	\$0.1483	C H 5%	
<u>Tab 100 mg</u>	158,727	\$58,300	\$0.3673	C H 5%	
<u>Tab 25 mg</u>	422,894	\$66,056	\$0.1562	C H 5%	
<b>Clozapine</b>					
Oral liq 50 mg per ml	94,768	\$16,423	\$0.1733	C H 5%	
<b>Cyclizine lactate</b>					
Inj 50 mg per ml, 1 ml ampoule	77,428	\$166,702	\$2.1530	C H 5%	
<b>Diazepam</b>					
Rectal tubes 5 mg	24,706	\$214,942	\$8.7000	C H 5%	
Rectal tubes 10 mg	427	\$3,490	\$8.1740	C H 5%	Not currently listed in Section B of the Pharmaceutical Schedule. Units are for a product delisted 1 December 2020.
<b>Dihydrocodeine tartrate</b>					
<u>Tab long-acting 60 mg</u>	4,541,326	\$650,908	\$0.1433	C H 5%	

sole supply

#=-rebate \*=-part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
<b>Droperidol</b>					
Inj 2.5 mg per ml, 1 ml ampoule				H 5%	
<b>Fentanyl</b>					
inj 10 mcg per ml, 100 ml premixed bag				H 5%	
<b>Fluoxetine hydrochloride [combined market]</b>					
Tab dispersible 20 mg, scored			\$0.0660	C H 5%	Pharmac reserves the right to award a single tender for dispersible tablets only for the whole fluoxetine solid oral dosage form market or two separate tenders for capsules and dispersible tablets.
<b>Fluoxetine hydrochloride [split market]</b>					
Cap 20 mg	22,752,868	\$788,159	\$0.0346	C H 5%	Pharmac reserves the right to award a single tender for dispersible tablets only for the whole fluoxetine solid oral dosage form market or two separate tenders for capsules and dispersible tablets.
Tab dispersible 20 mg, scored	1,632,158	\$107,722	\$0.0660	C H 5%	Pharmac reserves the right to award a single tender for dispersible tablets only for the whole fluoxetine solid oral dosage form market or two separate tenders for capsules and dispersible tablets.
<b>Haloperidol</b>					
<u>Inj 5 mg per ml, 1 ml</u>	110,126	\$237,322	\$2.1550	C H 5%	
<u>Oral liq 2 mg per ml</u>	95,502	\$22,768	\$0.2384	C H 5%	
<u>Tab 500 mcg</u>	1,142,218	\$71,160	\$0.0623	C H 5%	
<u>Tab 1.5 mg</u>	209,672	\$19,772	\$0.0943	C H 5%	
<u>Tab 5 mg</u>	231,261	\$68,731	\$0.2972	C H 5%	
<b>Levodopa with Benserazide</b>					
Cap 50 mg with benserazide 12.5 mg	1,731,136	\$238,031	\$0.1375	C H 5%	
Cap 100 mg with benserazide 25 mg	2,084,237	\$329,309	\$0.1580	C H 5%	
Cap 200 mg with benserazide 50 mg	256,137	\$67,236	\$0.2625	C H 5%	
Cap long-acting 100 mg with benserazide 25 mg	468,663	\$107,089	\$0.2285	C H 5%	
Tab dispersible 50 mg with benserazide 12.5 mg	687,351	\$91,074	\$0.1325	C H 5%	
<b>Levomepromazine</b>					
<u>Inj 25 mg per ml, 1 ml</u>	75,764	\$253,809	\$3.3500	C H 5%	
<u>Tab 100 mg</u>	6,834	\$2,853	\$0.4175	C H 5%	Preference for a scored tablet.
<u>Tab 25 mg</u>	27,100	\$4,363	\$0.1610	C H 5%	Preference for a scored tablet.
<b>Lidocaine [Lignocaine]</b>					
<u>Gel 2 %, 10 ml - 11 ml urethral syringe</u>	79,415	\$333,543	\$4.2000	C H 5%	
<b>Lidocaine [Lignocaine] hydrochloride</b>					
Inj 10%				C H 5%	Not currently listed in the Pharmaceutical Schedule.
Inj 10%, prefilled syringe				C H 5%	Not currently listed in the Pharmaceutical Schedule.
Spray - 10 mg dose per spray				H 5%	
Inj 1%, 5 ml	140,299	\$49,105	\$0.3500	C H 5%	Preference for plastic ampoules.
Inj 1%, 20 ml	784	\$1,882	\$2.4000	C H 5%	Preference for plastic ampoules.
<u>Inj 2%, 5 ml</u>	36,751	\$12,128	\$0.3300	C H 5%	Preference for plastic ampoules.
Inj 2%, 20 ml	4,875	\$6,289	\$1.2900	C H 5%	Preference for plastic ampoules.
<b>Lidocaine [lignocaine] hydrochloride with adrenaline</b>					
Inj 1% with adrenaline 1:100,000, 5 ml				H 5%	
<b>Lidocaine [Ligocaine] hydrochloride with chlorhexidine</b>					
Gel 2% with 0.05% chlorhexidine, 10 ml urethral syringe	13,604	\$140,557	\$10.3320	C H 5%	
<b>Methadone hydrochloride</b>					
<u>Tab 5 mg</u>	1,968,889	\$275,644	\$0.1400	C H 5%	
<u>sole supply</u>					

#=-rebate \*=-part charge @=ASP +=patent



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
Line Item					
<b>Metoclopramide hydrochloride</b>					
<u>Inj 5 mg per ml, 2 ml ampoule</u>	186,046	\$176,744	\$0.9500	C H 5%	
<b>Morphine sulphate</b>					
<u>Cap long-acting 10 mg</u>	3,983,371	\$816,591	\$0.2050	C H 5%	
<u>Cap long-acting 30 mg</u>	1,006,545	\$301,964	\$0.3000	C H 5%	
<u>Cap long-acting 60 mg</u>	354,431	\$216,912	\$0.6120	C H 5%	
<u>Cap long-acting 100 mg</u>	211,414	\$150,738	\$0.7130	C H 5%	
<b>Nortriptyline hydrochloride</b>					
<u>Tab 10 mg</u>	14,550,422	\$355,030	\$0.0244	C H 5%	
<u>Tab 25 mg</u>	9,946,263	\$330,415	\$0.0332	C H 5%	
<b>Olanzapine</b>					
Inj 210 mg vial	2,284	\$575,568	\$252.0000	+ C H 5%	Special Authority restrictions may apply.
Inj 300 mg vial	11,811	\$4,889,754	\$414.0000	+ C H 5%	Special Authority restrictions may apply.
Inj 405 mg vial	8,592	\$4,330,368	\$504.0000	+ C H 5%	Special Authority restrictions may apply.
<b>Ondansetron</b>					
<u>Tab 4 mg</u>	2,140,978	\$114,756	\$0.0536	C H 5%	
<u>Tab 8 mg</u>	682,384	\$62,370	\$0.0914	C H 5%	
<b>Paracetamol</b>					
Suppos 25 mg				H 5%	
Suppos 50 mg				H 5%	
<b>Paracetamol with codeine</b>					
Tab paracetamol 500 mg with codeine phosphate 30 mg				C H 5%	Not currently listed in the Pharmaceutical Schedule.
Tab paracetamol 500 mg with codeine phosphate 8 mg	43,318,899	\$1,148,384	\$0.0265	C H 5%	Restrictions may apply.
<b>Paroxetine</b>					
<u>Tab 20 mg</u>	10,208,732	\$409,472	\$0.0401	C H 5%	Tablet must be scored.
<b>Pramipexole hydrochloride</b>					
<u>Tab 0.25 mg</u>	1,568,989	\$96,022	\$0.0612	C H 5%	
<u>Tab 1 mg</u>	149,236	\$30,937	\$0.2073	C H 5%	
<b>Propofol</b>					
Inj 10 mg per ml, 100 ml				H 10%	Preference may be for an EDTA containing product.
Inj 10 mg per ml, 20 ml				H 10%	Preference may be for an EDTA containing product.
Inj 10 mg per ml, 50 ml				H 10%	Preference may be for an EDTA containing product.
<b>Ropinirole hydrochloride</b>					
<u>Tab 1 mg</u>	969,152	\$45,572	\$0.0470	C H 5%	
<u>Tab 2 mg</u>	373,946	\$24,396	\$0.0652	C H 5%	
<u>Tab 250 mcg</u>	1,484,608	\$50,358	\$0.0339	C H 5%	
<u>Tab 5 mg</u>	31,700	\$4,717	\$0.1488	C H 5%	
<b>Sertraline</b>					
<u>Tab 50 mg</u>	16,471,475	\$505,114	\$0.0307	C H 5%	
<u>Tab 100 mg</u>	7,438,978	\$399,220	\$0.0537	C H 5%	
<b>Sucrose</b>					
Oral liq 25%				H 5%	Preference for a smaller pack size (25 - 50 ml)
<b>Sumatriptan</b>					
<u>Inj 12 mg per ml, 0.5 ml</u>	47,968	\$815,456	\$17.0000	C H 5%	Price should include autoinjector
<b>Tetrabenazine</b>					
<u>Tab 25 mg</u>	129,150	\$105,049	\$0.8134	C H 5%	
<b>Tranylcypromine Sulphate</b>					
Tab 10 mg	288,435	\$132,334	\$0.4588	C H 5%	

sole supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Oncology Agents and Immunosuppressants**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Azathioprine</b>					
Inj 50 mg				H 5%	
Tab 50 mg	4,250,975	\$323,074	\$0.0760	C H 5%	Preference for blister packaging.
Tab 25 mg	384,005	\$47,041	\$0.1225	C H 5%	Preference for blister packaging.
<b>Bortezomib</b>					
Inj 3.5 mg				+PCT H 5%	
<b>Busulfan</b>					
Inj 6 mg per ml				PCT H 5%	
<b>Capecitabine</b>					
Tab 150 mg	149,028	\$24,838	\$0.1667	C H 5%	
Tab 500 mg	684,442	\$279,478	\$0.4083	C H 5%	
<b>Fludarabine phosphate</b>					
Inj 50 mg				PCT H 5%	
<b>Fulvestrant</b>					
Inj 50 mg per ml, 5 ml	7,417	\$3,960,678	\$534.0000#	C H 5%	
<b>Lomustine</b>					
Cap 10 mg	437	\$2,897	\$6.6295	PCT C H 5%	
Cap 40 mg	624	\$12,453	\$19.9575	PCT C H 5%	
<b>Temozolomide</b>					
Cap 100 mg	19,134	\$137,688	\$7.1960	C H 5%	Special Authority restrictions may apply.
Cap 140 mg	639	\$6,405	\$10.0240	C H 5%	Special Authority restrictions may apply.
Cap 20 mg	11,277	\$36,943	\$3.2760	C H 5%	Special Authority restrictions may apply.
Cap 250 mg	530	\$9,152	\$17.2680	C H 5%	Special Authority restrictions may apply.
Cap 5 mg	4,438	\$8,104	\$1.8260	C H 5%	Special Authority restrictions may apply.
<b>Thiotepa</b>					
Inj 100 mg				PCT H 5%	
Inj 15 mg				PCT H 5%	

**Respiratory System and Allergies**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Cetirizine hydrochloride</b>					
Tab 10 mg	48,533,858	\$543,579	\$0.0112	C H 5%	Preference for a pack size of 90 tablets.
<b>Loratadine</b>					
Tab 10 mg	35,731,719	\$603,866	\$0.0169	C H 5%	Preference for a pack size of 90 tablets.
<b>Montelukast</b>					
Tab 10 mg	1,521,199	\$214,596	\$0.1411	C H 5%	
Tab 4 mg	204,511	\$31,043	\$0.1518	C H 5%	
Tab 5 mg	563,369	\$85,514	\$0.1518	C H 5%	
<b>Pholcodine</b>					
Oral liq 1 mg per ml				H 5%	Preference for a smaller pack size ( 100 ml to 200 ml).

**Sensory Organs**

Chemical Name Line Item	Units	Cost	Unit Subsidy	ABA Limit	Comments
<b>Chloramphenicol</b>					
Eye drops 0.5%	1,210,315	\$186,389	\$0.1540	C H 5%	Unit subsidy expressed as "per ml".
Eye oint 1%	655,950	\$203,345	\$0.3100	C H 5%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Sensory Organs**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>ABA Limit</b>	<b>Comments</b>
Line Item					
<b>Olopatadine</b>					
<u>Eye drops 0.1%</u>	1,129,540	\$496,998	\$0.4400#	C H 5%	For products containing Benzalkonium chloride (BAK), Pharmac reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy expressed as "per ml".
<b>Sodium cromoglicate</b>					
<u>Eye drops 2%</u>	255,970	\$91,637	\$0.3580	C H 5%	For products containing BAK, Pharmac reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy expressed as "per ml".
<b>Sodium hyaluronate [hyaluronic acid]</b>					
Inj 10 mg per ml, 0.85 ml syringe				H 5%	Please note in Tender Bid if product is dispersive or cohesive viscoelastic.
Inj 14 mg per ml, 0.55 ml syringe				H 5%	Please note in Tender Bid if product is dispersive or cohesive viscoelastic.
Inj 14 mg per ml, 0.85 ml syringe				H 5%	Please note in Tender Bid if product is dispersive or cohesive viscoelastic.
Inj 30 mg per ml				H 5%	Please note in Tender Bid if product is dispersive or cohesive viscoelastic.
Inj 23 mg per ml, 0.6 ml syringe				H 5%	Please note in Tender Bid if product is dispersive or cohesive viscoelastic.